AGTC Announces US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa – GlobeNewswire (press release)
|
AGTC Announces US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
GlobeNewswire (press release) GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene … |
